Eloxx Pharmaceuticals CEO Stock Option Repricing Initiative
Company Announcements

Eloxx Pharmaceuticals CEO Stock Option Repricing Initiative

Eloxx Pharmaceuticals Inc (ELOX) has shared an update.

Eloxx Pharmaceuticals has initiated a stock option repricing for their CEO’s eligible options under the 2018 Equity Incentive Plan, reducing the exercise price to $0.90, aligning with the closing stock price on March 25, 2024. This move affects both vested and unvested options, significantly lowering the weighted average exercise price from $37.47 for nearly 200,000 shares owned by CEO Sumit Aggarwal, potentially making it more attractive for investment and retention purposes.

See more insights into ELOX stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskEloxx Pharmaceuticals Reprices CEO Stock Options
TheFlyEloxx Pharmaceuticals provides ELX-02, ZKN-013 program updates
TheFlyEloxx Pharmaceuticals treatment of Alport Syndrome granted FDA orphan status
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App